So, this treatment doesn't look so good for patients with severe cases, but says nothing about non-severe cases. > The preliminary findings of this study sugg

So, this treatment doesn't look so good for patients with severe cases, but says nothing about non-severe cases. > The preliminary findings of this study suggest that the higher CQ dosage should not be recommended for critically ill patients with COVID-19 because of its potential safety hazards, especially when taken concurrently with azithromycin and oseltamivir. These findings cannot be extrapolated to patients with nonsevere COVID-19. From Dr Raoult's study, we see almost the same claim, except that there are good observed results for non-severe cases: > The HCQ-AZ combination, when started immediately after diagnosis, is a safe and efficient treatment for COVID-19, with a mortality rate of 0.5%,in elderlypatients. It avoidsworsening and clearsvirus persistence and contagiosity in most cases https://www.mediterranee-infection.com/wp-content/uploads/2020/04/Abstract_Raoult_EarlyTrtCovid19_09042020_vD1v.pdf https://www.mediterranee-infection.com/wp-content/uploads/20... So, this appears to verify a claim in Dr Raoult's study.